|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||COLO 699 N|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: COLO 699 N (ECACC 93052608)|
|Keywords:||Human lung cancer|
|Cell Line Description:||Derived from the pleural fluid of a 57 year old female with lung cancer. Please note: This cell line was found to be indistinguishable from cell lines RPMI 7932 & COLO 738 by STR PCR DNA profiling. At ECACC the STR PCR profile of all stocks of this cell line match the profile of the original source material received at ECACC. However, it is not clear if the cell lines COLO 699N, RPMI 7932 & COLO 738 were originally derived from the same individual as the profiles suggest. The cell lines COLO 699N, RPMI 7932 & COLO 738 were received from the same depositor. If we are able to obtain clarification of the relationship between these cell lines this information will be updated.|
|Tissue of Origin:||lymph node|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm² using 0.05% trypsin/EDTA; 5% CO2; 37°C.|
|Culture Medium:||RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Prof G Moore, Colorado Oncology Foundation, Denver General Hospital, Co 80204-4507|
|References:||Cancer Genet Cytogenet 1993;69:108|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.